Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

193.22
+1.100.57%
Post-market: 192.00-1.2200-0.63%19:59 EDT
Volume:7.76M
Turnover:1.50B
Market Cap:465.34B
PE:18.67
High:193.60
Open:192.50
Low:191.68
Close:192.12
52wk High:194.40
52wk Low:140.68
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.76
T/O Rate:0.32%
Dividend:5.08
Dividend Rate:2.63%
EPS(TTM):10.35
EPS(LYR):5.84
ROE:33.80%
ROA:7.61%
PB:5.93
PE(LYR):33.07

Loading ...

Income Investing: Where to Find the Yield That's Lacking In S&P 500 Funds -- Barron's

Dow Jones
·
Yesterday

BRIEF-EMA's CHMP Recommends Against Sanofi's Rezurock

Reuters
·
Oct 17

U.S. Stocks to Watch: Novo Nordisk, Eli Lilly, Oracle, Micron, Zions Bancorp, American Express, and More

Dow Jones
·
Oct 17

Kenvue Stock (KVUE) Plunges on Legal Woes Related to Talc Products

TIPRANKS
·
Oct 17

JNJ International Accelerates Global Expansion with KOTRA: Launches Buyer Discovery Project in Five Countries

prnewswire
·
Oct 17

PRESS DIGEST-Financial Times - October 17

Reuters
·
Oct 17

Johnson & Johnson Publishes Transcript of Third Quarter 2025 Earnings Conference Call

Reuters
·
Oct 17

Why Kenvue Stock Tumbled by 13% on Thursday

Motley Fool
·
Oct 17

New York Closing Stocks

Dow Jones
·
Oct 17

Kenvue Stock Tumbles on a New Challenge. It Isn't Tylenol This Time. -- Barrons.com

Dow Jones
·
Oct 17

Johnson & Johnson Says Tecvayli With Darzalex Faspro 'Superior' to Standard of Care in Multiple Myeloma

MT Newswires Live
·
Oct 16

Citi cautious on Kenvue after talc lawsuit filed in UK

TIPRANKS
·
Oct 16

Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase

Motley Fool
·
Oct 16

Scott Bessent Says US Investment Boom 'Sustainable' Under Trump: 'The Only Thing Slowing Us Down...'

Benzinga
·
Oct 16

Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Plus DARZALEX FASPRO® in Relapsed/Refractory Multiple Myeloma

Reuters
·
Oct 16

Johnson & Johnson Receives U.S. FDA Priority Review for Akeega® (Niraparib and Abiraterone Acetate Dual-Action Tablet) in Brca-Mutated Metastatic Castration-Sensitive Prostate Cancer

THOMSON REUTERS
·
Oct 16

BRIEF-J&J Tecvayli Plus Darzalex Faspro Combination Regimen Significantly Improves Progression-Free Survival & Overall Survival Versus Standard Of Care

Reuters
·
Oct 16

J&J: Overall Safety Profile of Tecvayli in Combination With Darzalex Faspro Consistent With Known Safety Profiles of Each Monotherapy

THOMSON REUTERS
·
Oct 16

J&J: Independent Data Monitoring Committee Recommended Unblinding Phase 3 Majestec-3 Study

THOMSON REUTERS
·
Oct 16

Johnson & Johnson Faces UK Lawsuit Over Talc Products

MT Newswires Live
·
Oct 16